LUMOS PHARMA, INC. financial data

Location
Austin, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 07 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 462% % -53%
Debt-to-equity 79% % 211%
Return On Assets -130% % -138%
Operating Margin -1648% % 19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8,648,618 shares 9.3%
Common Stock, Shares, Outstanding 8,648,243 shares 9.3%
Weighted Average Number of Shares Outstanding, Basic 8,327,488 shares 4.4%
Weighted Average Number of Shares Outstanding, Diluted 8,327,488 shares 4.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,205,000 USD 27%
Revenue from Contract with Customer, Excluding Assessed Tax $2,205,000 USD 27%
Research and Development Expense $22,687,000 USD 12%
General and Administrative Expense $15,847,000 USD -6.1%
Operating Income (Loss) $36,329,000 USD -2.5%
Nonoperating Income (Expense) $1,413,000 USD -45%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $7,467,000 USD 10%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $34,916,000 USD -6.4%
Earnings Per Share, Basic -4 USD/shares -6.7%
Earnings Per Share, Diluted -4 USD/shares -6.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,519,000 USD -62%
Assets, Current $17,274,000 USD -64%
Operating Lease, Right-of-Use Asset $187,000 USD -30%
Assets $17,461,000 USD -63%
Accounts Payable, Current $1,455,000 USD 198%
Employee-related Liabilities, Current $2,895,000 USD 3.1%
Accrued Liabilities, Current $4,920,000 USD -11%
Liabilities, Current $6,505,000 USD 6.4%
Operating Lease, Liability, Noncurrent $42,000 USD -71%
Liabilities $12,547,000 USD 2.3%
Retained Earnings (Accumulated Deficit) $186,976,000 USD -23%
Stockholders' Equity Attributable to Parent $4,914,000 USD -86%
Liabilities and Equity $17,461,000 USD -63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $12,894,000 USD -40%
Net Cash Provided by (Used in) Financing Activities $5,000 USD 98%
Net Cash Provided by (Used in) Investing Activities $1,000,000 USD
Common Stock, Shares Authorized 75,000,000 shares 0%
Common Stock, Shares, Issued 8,679,053 shares 9.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $11,899,000 USD 0.58%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,519,000 USD -62%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $34,912,000 USD -6.3%
Operating Lease, Liability, Current $130,000 USD 3.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $192,019,000 USD 2.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $2,000 USD -78%
Share-based Payment Arrangement, Expense $1,870,000 USD -22%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%